Literature DB >> 4751911

Intra-arterial infusion therapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388) for malignant melanoma.

L H Einhorn, C M McBride, J K Luce, E Caoili, J A Gottlieb.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4751911     DOI： 10.1002/1097-0142(197310)32:4<749::aid-cncr2820320403>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  5 in total

1.  A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques.

Authors:  K I Bland; A K Kimura; D E Brenner; M A Basinger; M Hirsch; I F Hawkins; K K Pierson; E M Copeland
Journal:  Ann Surg       Date:  1989-01       Impact factor: 12.969

Review 2.  Combined modality therapy of malignant melanoma.

Authors:  E M Hersh; J U Gutterman; C M McBride
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

3.  Local hyperthermia and systemic chemotherapy for treatment of recurrent melanoma.

Authors:  F Di Filippo; S Carlini; R Garinei; P Perri; M Anzà; F Ferranti; E Saracca; M Schiratti; F Cavaliere; R Cavaliere
Journal:  World J Surg       Date:  1995 May-Jun       Impact factor: 3.352

4.  The use of regional chemotherapy in the management of malignant melanoma.

Authors:  E T Krementz; R D Carter; C M Sutherland; M Campbell
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

5.  Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules.

Authors:  H Breithaupt; A Dammann; K Aigner
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.